Company intelligence / Profile preview
Ornovi
Irvine, California, United Statesornovi.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ornovi is developing selective JAK3/ITK dual inhibitors for inflammatory and autoimmune diseases. Their lead candidate, OR-101, has shown positive preclinical efficacy in animal models for alopecia areata and other skin conditions. The company reported stimulation of hair growth in murine models with their next-generation JAK3 inhibitor. No clinical results have been published yet.
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Small moleculesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Ornovi.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ornovi.